INTRODUCTION
In the last d ecad e a dramat ic change in the social patterns of coca ine use has forced th e med ica l co mm u nity to witness th e devastation of a new epidemic. A "cocaine e pi demic" that seems so radically different from the fas h iona b le p reval e nce of cocai ne use in the early par t of th is century has filled medical, pediatric, psyc h iatric an d neo natal facilities and strained the limits of huma n and material resources.
O ne is encouraged, however , by the new public awareness o f the p robl em . T he federal govern ment has begun to address the need for treatme n t more d irectly. Knowledge of the medical consequences of cocaine use is more widesp read, due in par t to the vicissitudes of entertainers and ath letes who use cocaine. T he DSM-IlIR has recognized d iagnostic categories o f coca ine d epend ence a nd withdrawal that d raw upon recen t stud ies of cocaine users.
An ad d itional encou ragement lies in the clear description of ab st inence sym ptomatology. From an understand ing of phenomenology eme rges an attempt to alleviate symptoms th rough the use of medications. Medicatio n may be a tool to help addicts to lerate withdrawal and then bec om e e ngaged in the long-term psychosocial interventions that will probably be necessar y for continued abstinence and improved fun ctioning. This paper, aft er brie f co nsideration of background id eas in epidemiology, clinical descriptions and phar maco logy, will review medical treatments of withdrawal and d ependence . Recent epidemiologic studies of cocaine use have been reviewed in detail elsewhere (1) (2) (3) (4) , but a brief mention of important sta tist ics is in order.
A 1985 National Institute of Drug Abuse , Household Survey estimated that 3 million Americans a r e dependent on cocaine. About 2 5 mill io n Americans, including 40% of the population between ages 25 and 30, h a ve tried cocaine. About 5.8 % of high sch oo l seniors are current users.
Admissions to publicly-funded treatment cente rs, e mergency room visits that are cocaine related, and the number of cocaine r elated deaths increased approximately 15 fold between 1976 and 1986.
CLINICAL MANIFESTATIONS
Descriptions of the effects of cocaine o n the cardio vascul a r and nervous systems are widely available. However, understanding of cocaine's psychiatric effects has evol ved in recent yea r s. After brief mention of t he in te ractio n of cocaine with mood and thought processes, new ideas about absti nence symptoms will be presented.
Cocaine is classically described as a powerful e u p horic. Use of cocaine as an antidepressant though, has not gained favor. Despite Freu d's conviction (5) that cocain e was an effective therapy for depression , t h is h as not been corroborated e xp e r ime nta lly in 10 depressed patients at the National Inst itute of Mental Health (6) . Furthermore, Post noticed that coca ine is n ot o n ly ineffec tive as a treatment for depression but may also be capable of inducin g d ysphor ia (7) . He noticed that d ysphoria associated with stimulant intoxicati on is simi lar clinically to the depressed affect that often accompanies fulm in ant man ia , and that cocaine may potentiate sad affect in d epressed patients. T he t im e course of these ev ents is unclear and Post may have been d escribing what a re n ow u nde rsto od to be withdrawal phenomena.
Psychosis is a se ve re psychic manifestation o f cocaine use. T he se minal work o f Post (7) postulates a continuum o f stimulant induced affect ive an d psychotic sta tes with th e involvement of multiple neurochemical a berrations. Post has also reviewed the literature regarding stimulants as d eterminan ts of pathological behavio r and seizures through a mechanism sim ilar to electr ica l kind ling (8) . The assertion that stim u la nts may disrupt limbic fu nc tio n when used chronicall y, and through a kindling-like phenomenon, produce ch ronic affective and sch izop h ren ifor m syndromes, is a powerful id ea. Prelimin ary evi dence suggests that long term st im u la n t abuse may ca use degene r ation of dopa m ine r g ic neurons and lea ve the patient with an irre versibl e deficit in mood regu lation (1).
Gawin a n d others (1 ,9) have produced a detailed d escri ptio n of symptoma tology when 30 coc a ine abusers were obse rved in abstinence . T hey divide abst inence into " crash, " "withdrawal ," a n d "extinc tio n" phases.
The cr ash phase foll o ws a b inge . Acute d ysp horia, anxiety a n d craving are rep laced wit h in a fe w hours b y h yp ersomnolence a n d h ype r p hag ia . It is diffi cul t to d istinguish crash sym p toms fr om major depressio n , but o ne may suspect a p rima r y psychiatric d iso rder if neuro vegetative sym ptoms persist after slee p has returned to normal a n d prol onged abs t ine nce ha s b ee n ac hieved. The cra ving to a llev ia te cr as h effects is di sconti nuous, unlike the craving seen with alc ohol an d o p iate withdrawal.
Withdraw al sym p toms include a ne r gia, a n hedonia, lack of interest an d varia b le le vels of craving. T hese symptoms seem to peak at 12-96 h ou rs. Symptoms then remain in a fluctuating pattern a n d are generall y not severe e n ou gh to be confused with major depression. Lethargy a nd d ysphoria usually improv e by 4-5 months of abstinence .
Extinction refers to th e brief, ep isod ic return of cravi ng fo r cocai ne brought a bo u t b y the influence of conditioned cues. Many sti m u li, such as objects or circu ms ta n ces formerl y associated with drug us e, and fa n tas ies or dreams of drug use may spark cra vin g. Su ch craving may return for man y mon t hs or e ve n yea rs. Ext inctio n is the removal of these conditioned cues.
Criticism of Gawin's model focu ses on its naturali sti c desig n and its neglect for recent reports of physical concomitants of a cocaine with drawal syndrome , (m uscle pains, chills, tremor) ( 10) . T h is is an elegant framework for furth er elucid ation of withdrawal phenomena, however.
CO-MORBIDITY
The relationship between psychopathology a nd d rug abuse is controversial. Psychodynamic formulation s of su bs ta n ce abuse pathol ogy have been well su m mar ize d by Wurmser (1 1). In hi s view, addict s exh ibi t r u di mentary ca paci ty fo r use o f symbol and fantasy, inability to defend aga inst strong affects, a chronic sea rc h ing to replace inadequate objects, self d estruct iveness a nd regressi ve gratification of narcissistic needs. Life 's difficulties co n tin ua lly prese nt a series of narcissistic injuries to addicts which are defended agains t by drug use .
Only two studies have e valuated cocaine abuse rs fo r DSM-III , Axi s 1 co-mo r b id ity and these are su m ma r ized by Gawin and Klebe r (9) . Affective di sorders, including major depression, d ysthymia and a ty p ical depressio ns a re found in 30 % of users, with minor depressions comprising the maj ority of this group. Twenty percent of users are bipolar or cyclothymi c, a nd a pproximately 5% may be seen as having residual attention deficit di sorde r.
Interestingly, 64% of cocaine users with DSM-III affec tive d iagn oses prefer the intranasal route and have shorter "runs," su ggesting a cessation of drug use wh en d ysphoria is ameliorated (9) .
Khantzian has been a major proponent for th e co ncep t of d rug abuse as se lf medication for psychiatric di sorders ( 12) . While Post 's N IM H study fail ed to show e up ho r ic response to cocaine in subj ects wit h maj or d epression , Khantzian feels that patients with dysth ymia or a typ ical depression may indeed respond to stimulants and hence the basis for h is " self m edication" h ypo t hesis. Khantzian also believes cyclothymic patients sel f-med ica te in order to reverse d ysth ymia and maintain stab le hypoman ia. He also proposes that pa tie n ts with attention deficits may be able to improve their function with cocaine (9) . Fle me nb au m (13 ) al so was one of the first to see substance abuse as a parapsychiatri c symptom in patients with affective disorders.
Studies of self-administration of cocaine in animal s a nd hum a ns suggest that the incredibly pleasurable "reward" provided by cocaine may produ ce addictive behavior in indi viduals not particularly predisposed b y a psychi atr ic diagnosis. Fischman (14, 15) has shown that humans will self adm ini ste r IV solutions of cocaine in a manner similar to animal models and h as d ocu me n ted acute tol erance to the cardiovascular and su bj ective euphoric effec ts of cocaine . These data suggest that coca ine is indeed a powerfull y addicti ve su bstance and that psychopathology is not necessarily a precursor of addiction.
ABUSE OF OTHER DRUGS
A problem which co n fo u nds treatment of coc ain e users as much as ps ychiatric co-morbidity is the presence of multiple subs ta nces of ab use. Klebe r (16) reports that 50% of cocaine users also abuse alcohol , 30 % use marih ua na , 8 % use amphetamines, 5 % use tranquilizers and 4 % use opiates. Experie nce in inner cit y se ttin gs leads one to believe that polydrug abuse is the norm . A we ll known phenomenon amongst heavy cocaine users is the d evelopment of a ne ed to " t itra te" cocaine binges with depressant drugs. Man y users tu rn to alcohol, tranquilizers or narcotics to enabable sleep after ch r o n ic cocaine in gest ion.
Use of marijuana almost inevitably precedes cocaine use (4) . Ninety-Six percent of cocaine users are former or concurrent users of marijua na and the likelihood of cocaine use increases with the lifetime frequ ency of marijua na use .
PHARMACOLOGY
Many of the current physiologic concepts concernin g n euroadap ta t io n to chronic cocaine abuse and the production of an a bs tinence syn drome h ave th eir basis in early models of intracranial self-stimulation. It has bee n known for nearly thirty five yea rs that animals will self administer electr ica l stimuli to "pleasure centers" of the brain (17) . The electrical stim u li are h ypothesized to activate certain neurotransmitter mediated " re wa r d pathwa ys." It has also been found that animals will self administer central nervous syste m st im u lants, especia lly when they are applied directly to reward pathwa ys. Huma ns also self administer cocaine in laboratory st ud ies (18) . Stimulant sel f ad ministration is probably mediated largely by mesocortical and mesolimbic dopam ine r gic proj ections.
Controversy arises wh en one tries to determine exac tly which transmitters or which element of transmitter chemistry is affected by chronic stimulant abuse and is therefore responsible for the neuroadaptation of ad d ict ion . Cocaine and other stimulants cause neuronal release of norepinephrin e , dopam ine , and possibly acetylcholine and serotonin. The re-uptake of th ese am ines is also blocked by cocaine. Supersensitivity of ,B-adrenergic, a-adren ergic and dopaminergic receptors occurs with prolonged cocaine ad m in istra t ion . Bet a-recep to r supersensitivity is thought to contribute to depressive affect sta tes, a nd th is may account for post-cocaine dysphoria.
The most compelling neurochemical explanations fo r cocai ne ind uced euphoria and post-cocaine dysphoria implicate dopamine. A rece nt study p roposes that dopamine re-uptake inhibition is the principal determinant of dependence (19) . Lesions produced in tegmental dopaminergic a r eas wit h 6-hydroxydopamine decrease self administration of cocaine (20) . Pimozide (a dopamine receptor blocker), but not phentolamine or phenoxyb enzam ine (noradrenergic blockers), blocks self administration of cocain e (21 ). T he a bility of rats to discriminate for cocaine is attenuated by pimozide, haloperid ol and chlorpromazine, but this effect is not observed with propranolol , ph e noxyb enzamine, a -methyl-para-tyrosine, or physostigmine (22) . It is also well kn o wn that neuroleptics block amphetamine induced psychotic symptomatology in human s (23) . Reports that cocaine users develop hyperprolactinemia ma y indicate a chronic depletion of dopamine (24) . Some chronic cocaine users ha ve also been observed to develop "pseudoparkinsonism" (25) . Preliminary PET sca n data from cocaine addicts demonstrate disordered DOPA utilization in th e striatum when 18-Auoro-DOPA is used as a tracer (26) . Though this evidence seems to favor an hypothesis of dopamine hypofunction or depletion , it must be r eme mbered that the evidence is not conclusive, and one must not be tempted to readi ly accept the "one transmitter-one disease" model (27) .
Cocaine's addictive potential also depends on the pharmacologic properties of the different forms of abused cocaine. Intranasal , freebased and intravenous cocaine are the patterns of use most commonly encountered, and th ere are significant pharmacologic differences between them (28).
Intranasal cocaine HCI requires 3-5 minutes for onset of actio n and ha s a mean half life of about one hour. Users commonly repeat the dose every 15-20 minutes to maintain a high.
Intravenous cocaine HCI produces a " r ush" in 30-45 seconds and has a hal f life of 10-20 minutes. The quick onset of action and shorter half life increase th e addictive potential. Since the user must administer doses more frequen t ly, in ever increasing amounts, tolerance is achieved more rapidly than wit h intranasal use.
Freebase cocaine is a basic salt of cocaine. Basic form s of cocaine are preferred for cocaine smoking because they have a lower tempera tu re of volatilization and are more lipid soluble than the HCI salt. " Crack" is a form of cocaine b ase which has been extracted with sodium bicarbonate. Wh en basic cocaine is smoke d it is a bsor bed very effic iently by the pulmonary vasc u latu re. A rush is ob ta ined in 8-10 seco nds and the hi gh remains for onl y 5-10 m inu tes. H ence , crack's rep u tatio n as the most ad d ict ive form of cocaine .
PHARM ACOTH ER API ES OF COCAI N E DEP EN DENCE
T he ul t ima te goa l of pha r macol ogic trea t me n ts is to obtain long te rm abs tinence. Abs tinence in itself may be a measurable effect from pharmacol o gic tr ea tm e n ts. H owe ver, medicatio ns may also bl ock the acute euphoric effects of cocaine, a nd may be effective r e m ed ies for wit hdrawal symptomatology. Block ed eup horia a nd impro ved with drawa l symptoms are variables that medicati o ns ma y affec t a nd thereby fac ilitate a bs tinence. Several different agents ha ve bee n stud ied for th e se effects.
ANT IDE PRES SANTS
Because chronic cocai ne abuse h as b ee n associated with in creased f3-adrenergic, a-adrenergic an d d o pa m ine r gic receptor sensiti vit y, a ntidepressants have been suggested as a therapy for cocaine withdrawal. The rational e fo r thi s choice lies in the abi lity of antidepressants to induce f3-adrenergic receptor subsensitivity after a period of time corresponding to clinical improveme nt of d epressed affect. A nti depressants ha ve been evaluated as agents for : blockade of acute , cocaine induced e up h or ia, for reduc tion of withdrawal associated a n hed onia , d ysphoria a nd cravi ng, a nd fo r e ffec tors of p ro longed abstinence .
Ten n a n t a n d Rawson (29) r eported an open tria l oflow dose desiprami ne in 14 cocaine a nd 8 a m p heta m ine a busers. T hey fel t t hat cocaine abstinence was im p roved (5 pat ie n ts relapsed within 45 da ys of admission) and that d ysph oria , craving, and sleep disturbance were reduced. Three of22 subject s reported th a t d esipra min e blocked the effects of cocaine or amphetamine . The y ba sed th eir selection of desipramine on its ability to increase synaptic norepinephrine , whi ch ma y b e d epl e ted in chronic cocaine use , and not the drug's ability to d ecrease f3 rece pto r sensitivity . H e n ce th eir tria l lasted on ly seven days.
Rosecan (3 0) reported substantia l reductio n in cocaine use in 80% of subjects wit h therapeut ic d oses of imipramine (100-300 mgs./da y). Ro secan a lso adm inis te red 1000 m g. of tyrosi ne in the morn ing and 1000 mg . of tryp tophan at b edtime , a nd anecdotally observed that acute euphoria was b locked an d tha t wit hdrawal associated craving was diminished.
Gawin a n d Klebe r (3 1) conducted an open trial of desipramin e in th e rape ut ic doses (200 mg./day) in six users who had failed to stop cocaine use wit h psycho t h e rap y alone. All subjects eventually became abstinent and quantita ti ve measures of cravi ng were reduced by the third week of treatment. Decreased cravi ng occurred in subjects regardless of coexisting psychiatric diagnosis.
These authors report a second trial of26 patients without a ffect ive d iso rd er who had fai led to become abstinent after four weeks of psychotherapy a nd were treated with desipramine, lithium, methylphenidate or psychotherapy (32) . Eighty percent of subjects with depressive symptoms who were treated with desipramine were abstinent for four weeks after nine weeks of drug treatment. Psychotherapy produced abstinence in 35 %. No lithium responders were noted and methylphenidate was discontinued because patients tended to ex h ib it increased craving after 2 weeks of treatment.
Rowbotham et al (33) performed a well controlled study evalua t ing t he possibility that serotonergic re-uptake blockade by an antidepressant may block acute euphoria with cocaine. They also postulated that antidepr essants affecting serotonergic uptake ma y be safer in cocaine abusers since norepin eph r ine reuptake blockade by antidepressants and cocaine together may be synergistic and dangerous. When subjects were pretreated with 100 mg. o f trazod one , a 2 mg./kg. dose of cocaine still produced euphoria although th e sym pa thom imetic effects of cocaine were diminished.
One case report exists of 200 mg./day of trazodone producin g rapid improvement in withdrawal symptoms and effecting abstinence o f 11 mo n ths. The authors suggest that trazodone's lack of anticholinergic e ffec ts th at could potentiate the sympathomimetic effects of cocaine ma y make trazodo ne a more acceptable treatment than standard tricyclic antidepressants (34 ) .
Baxter (35) reported two cases in which dysphoria and h ypersomnole nce after the abrupt cessation of cocaine use were improved within 1-2 d ays after initiation of desipramine treatment.
Giannini et al divided 20 cocaine abusers into t hose treated wit h 150 mg./day of desipramine and those receiving 25 mg./day o f diph enh yd ram ine as placebo. They used the Hamilton Depression Rating Scal e and clinical indices to assess symptomatology and found that the placebo group d eveloped sig nificant depression between days 0 and 20 of abstinence. Desipramine significantly reduced depression between days 20 and 40 (36) .
Gawin (32) has reported an ongoing double blind study co mpar ing desipramine, lithium and placebo in 75 cocaine abusers. Data ha ve been co llected on 24 patients and reveal significant decreases in cocaine use and in craving from four weeks after initiation of desipramine treatment. Plasma le vels were also monitored weekly and seem to suggest that cocaine addicts ma y require hi gher plasma levels than depressed subjects.
LITHIUM
Work in the 1970's demonstrated that the behavioral man ifestatio ns of amphetamines and cocaine could be attenuated in laboratory animals wit h lithium treatment (37) .
Angrist and Gershon (36) selected 8 patients with diverse psychi atric p roblems from an inpatient unit, and after stabilization, assessed th e effec ts of 0.5 mg./kg. of d-arnphetamine on subjects before and after treatme nt wit h lithium. They felt the attenuation of behavioral amphetamine effect s was variable but that the pressor response of amphetamine was attenuated uniforml y.
Amphetamine abuse was spo nt a neo usly discontinued in 2 patients who cou ld not experience euphoria from amphetamines while recei ving lithium (39) . Cronson and Flemenbaum reported 5 anecdotal cases in whi ch coc aine induced euphoria was prevented by lithium treatment (40) .
Scott and Mullaly reported on 2 heavy cocaine users wh o had d e vel oped chronic refractory psychoses and were successfully treated with lithiu m (4 1). A third patient with psychotic depression also improved and d enied e uphoric effects of cocaine while taking lithium.
Gawin and Kleber, in their open trial, found four of five cycloth ym ic patients treated with lithium to be abstinent at three months (3 1). Patients wit h DSM-I I I diagnoses of depression or dysthymia did not improve with lithium , an d lithium did not appear to b lock cocaine induced euphoria.
Gawin and Kleber (32) in their ongoing double blind study have foun d th at lithium reduces craving rapidly and for about one week. Craving and use of cocaine appeared to increase to baseline levels after this period.
BROMOCRIPTINE, AMANTADINE, L-DOPA
Because cocaine acutely increases synaptic release of dopamin e , bl ocks the re-uptake of dopamine, and may chronically lead to a dopamine depletion sta te, drugs affecting dopaminergic systems have begun to be studied. Bromocripti ne is an ergot derivative that has agonistic effects at dopamine receptors in various brain sites. Amantadine releases dopamine and norepinephrine from neuronal storage sites and slows re-uptake of dopamine and norepinephrine.
A small double blind study comparing placebo to a single dose ofbromocriptine (0.625 mg.) in two cocaine abusers with dysphoria and intense craving resulted in marked improvement in self rating of craving with bromoc r ip tine in six repeated trials (42) .
An anecdotal report on 7 users with DSM-III diagnoses of cocaine ab use and attention deficit disorder (ADD) found global improvement of atten tion and craving when bromocriptine was begun at 0.625 mg. t.i.d., and increased to a range of 7.5-12 .5 mg./day. These patients were abstinent during foll ow-up periods ranging from 3 to 9 months (43) .
Tennant and Sagherian (44) performed a double blind study of 14 use rs comparing bromocriptine (5.0-7.5 mg./day) with amantadine (100-300 mg./ day). Only one subject treated with bromocriptine was able to co mp lete ten days of treatment due to side effects. The subjective improvements in crav ing an d dysphoria were similar for bromocriptine and amantadine. However, th e " mea n dail y withdrawal score" indicated better performance with amantadine. T hese patients also received daily doses of tyrosine and tryptophan , and though this would not confound differences between bromocriptine and amantadine , th ese amino acids may provide some palliative effect in themselves. Bromo cr ip tine was also reported to block cocaine induced euphoria, and the autho rs postulate that bromocriptine may be well suited to treatment of patients who r equire partial agonist/antagonist therapy similar to naltrexone. They also felt t hat amantadine was safer and more effective in an ambulatory setting.
Giannini et al (45) performed a double-blind study for six wee ks co mpari ng bromocriptine to placebo in 24 cocaine addicts. Patients rec ei vin g b ro mocr iptine (0.625 mg q.i.d.) had significant improvements on th e Br ie f Psyc hiatric Rating Scale when compared to placebo. The authors conclude th at b ro rnocr iptine is an effective and fast acting treatment for withdrawal.
An open trial of 10 mg. carbidopa and 100 mg. L-d opa (b .i.d. or t.i.d .) for 1-2 weeks in "several" cocaine abusers resulted in "some response" in an attempt to alleviate withdrawal symptoms (46) .
STIMULANTS
Stimulants such as methylphenidate are pharmacologicall y sim ilar to cocaine and share cross tolerance with cocaine. Khantzian (4 7) descr ibed a heavy cocaine user successfully treated with methylphenidate 15 mg. t.i.d . and po stulated a residual ADD leading to self medication with co ca ine .
A second report (48) of three patients also meeting some criteria for ADD further supported the self medication hypothesis. Patients sh ow ed impr ovemen t in withdrawal symptoms.
Methylphenidate was not effective in producing cocaine abstinence in five abusers without ADD symptomatology despite 2-5 week trials in dosages up to 100 mg. daily (49) .
Magnesium pemoline in doses of 75-225 mg./day was reported to be effective in 2 patients with presumed residual ADD. These patients experien ced improvements in withdrawal symptoms and in long term ab stinence (50) .
Gawin (32) has reported that methylphenidate actually increases cocaine craving after a 1-2 week period of treatment in patients without A DD and proposes that a mi ld euphoria associated with methylphenidate use acts as a conditioned cue to resume cocaine use. The possibility of toxic in teractions between stimulants and cocaine has not been evaluated full y and th is must be kept in mind, especially in patients likely to abuse stim u lants as well as cocai ne.
TYROSINE
Based on the hypothesis that cocaine depletes catecholami nes and tha t tyrosine may increase the synthesis of dopamine, norepinephrine a nd epinephrine, Gold et al (5 1) administered 0.1 mg/kg. of tyrosine to 6 ad d icts undergo ing withdrawal. Tyrosine had "consistent anti-withdrawal effect s" in a n u nspecified period of time. These data are interesting and merit furth er in vestigatio n since the relative innocuousness and low abuse potential of tyrosin e are attractive.
S UMMARY OF DRUG THERAPIES JEFFERSO N JO UR NAL OF PSYCHIATRY
T h ree antidepressants, desipramine, imipramin e a nd trazod o ne , ha ve bee n stu d ied for their effects on cocaine addicts.
Desip ramine is mentioned as an age n t capable o f p roduci ng abstinence in 3 un controlled and 1 controlled study. The length o f a bst inence varies from one to man y months.
De sipramine improved with drawal symptomatology, including d ysphoria a n d craving, in 2 controlled and 3 uncontrolled studies. Desip ra m ine seemed to help immediately in 2 studies, but required 2-4 weeks for effectiveness in th e remainder.
One uncontrolled study states that desipramine block s acute eupho r ia associated with cocaine ingestion .
Imipramine, in one u nco n tro lled study, was found to be an e ffec tive agent for abstinence, withdrawal symptomatology and inhibition of ac ute eu p horia .
Trazodone was found to be effective in the treatment o f wit hdrawa l symptoms and in maintaining abstinence in one uncontrolled pape r. One con trolled st ud y found that trazodone did not block acute euphoria.
Lithium was found to be an e ffecto r of abstin ence when restricted to cyclo thy m ic patients in one uncontrolled study. In one co ntrolle d stud y lithium was felt to have a transient effec t on abstinence.
One controlled study found lithium to have a brie f, palli ati ve effect on withdrawal symptoms (fo r about one week).
Three uncontrolled reports found that lithium is a n in hi bitor of cocaine induced e up h o r ia . One uncontrolled study found this e ffec t to be lacking .
One case report has found lithium to b e an e ffec tive treatmen t for prolonged psychosis and/or ps ychotic d epression foll owing h ea vy, chronic cocaine use .
Bromocriptine, in three controlled studies and in o ne uncontrolled study, see ms to alleviate d ysphoria and craving. It seems to e xe r t this effec t rap idl y but is often associated with unpleasant side effects.
Bromocriptine is reported to have helped achieve abstinence in o ne uncontrolled and in one controlled study.
In one uncontrolled report bromocriptine was fe lt to block cocai ne-ind uced euphoria.
Amantadine was found to improve withdrawal symptoms in o ne con tro lled study.
L-dopa was found helpful in treating withdraw al sym p to ms in one ca se report.
Stimulants have been reported as effective treatments for with drawa l in two uncontrolled studies. However, one uncontrolled a nd o ne co n trolled study found that stimulants ma y wo rsen withdrawal sym p toms.
T wo uncontrolled reports cite sti m u la n ts as h elpful in ob taining abstinence. Man y o f the stu d ies in volvi ng st im u lants we re perfo r med on patients with presumpti ve , premorbid di agn o ses of a ttention d eficit d isorde r.
CONCL USION
This re vie w h as presented issues in e pidem io logic, clinical and neuropharma cologic aspect s of co caine ab use. Further r esearch into these areas can be e xpected to highlight sev e ra l questi ons. Further eluc idation of a cocaine withdrawal syndrome in large co hor ts, utilizing fu ll d escriptive and physiolog ic measures may more clearly d efine "subsy ndro rnes" th at wo u ld respond fa vorab ly to tailored form s of therapy. Long te rm prospect ive st udies evaluating th e presence o f pre-existent psychiatric di agnoses are necessa r y. The a tt e m p t to relate animal models to the neurophysiology of addicti ve beha viors in huma ns is a very murky area which under-scores the traditional gu lf between descriptive and pathophysiologic knowledge in psychiatry. Anatomic evi dence for dopamine d epletion in the b rain is still lacking , but presu m pti ve evi dence would suggest its presence in co caine abusers.
The psychopharmacologic management o f cocaine d e pe nde nce is a young and developing field. Current studies are quite p relimi na r y; for the most part an ecdotal and involve small numbers of patients. Since most reports are favorabl e , one is tempted to consider pharmacothe rapy as a n attractive adjunct to psychotherapy. Perhaps, with the allev ia tio n o f wit hd rawal symptoms, patients ar e made more " a vaila b le " for psychotherapeutic work.
From the work that is currently a vailable it would see m th a t lithium, dopaminergic agonists, and, possibly, in a proportion of ad d icts wit h premorbid attention deficits, stimulants, act rather qui ckl y to im prove craving and dysphoria during coca ine wit hd ra wal. Perhaps these agents will be seen as especially useful for the acute, inpatient management o f withdraw al. O ne is also hopeful that antidepressant therapy may emerge as an especially useful tool for treati ng the long term feelings of dysphoria and craving that so often preclude lo ng term abstinence.
